Inflammatory Bowel Disease

Geneoscopy is committed to research and development for patients with Inflammatory Bowel Disease (IBD). We leverage our proprietary RNA technology to help guide prognosis, treatment and disease monitoring.

Learn More

Inflammatory Bowel Disease

As of 2015, a reported 3 million individuals are living with an IBD diagnosis in the U.S.¹ Despite the high disease burden, obtaining a definitive diagnosis can take months and employing effective treatment to obtain remission can take years. The current gold standard for diagnosing and monitoring IBD is colonoscopy, which is expensive, invasive, and requires extensive bowel preparation. To mitigate the need for serial colonoscopies, noninvasive approaches have been developed. This includes survey-based approaches (e.g., Harvey-Bradshaw Index (HBI)), the Crohn’s disease activity index (CDAI), blood tests (e.g., erythrocyte sedimentation rate and C-reactive protein), and stool tests (e.g., calprotectin and lactoferrin). While existing noninvasive tests provide some ability to assist with the diagnosis, they cannot provide qualitative information on efficacious therapeutics or disease status.

Geneoscopy’s Solution

We are using our platform technology to create noninvasive diagnostics to guide prognosis, predict therapeutic response and assess mucosal healing for patients who are suffering from IBD. This research will ultimately provide physicians with noninvasive diagnostics that can improve outcomes in individuals with IBD.

Erica Barnell, MD, PhD working Geneoscopy's CAP/CLIA laboratory

For partnership inquiries, please send an email to:


  1. Prevalence of IBD | CDC. (2022, April 27).